The EU approval is the first for the drug, although the FDA in the US is due to deliver its verdict on it by 29th July, and ...

BIO 2025 this year came at a uniquely fraught moment for vaccination in the United States just days after HHS Secretary ...

Liquid biopsies are reshaping colon cancer detection, particularly in addressing the rise in early-onset cases.

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Elevidys has been given full approval to treat ambulatory patients with DMD, with an accelerated approval in non-ambulatory ...

That is the conclusion of a study in The Lancet, which has tracked the take-up of childhood vaccinations for diseases like ...

The STAAR trial showed that a one-shot dose of ST-920 – now known as isaralgagene civaparvovec – was able to improve kidney ...

Trying to tackle all challenges at once will likely cause even more issues in the future; instead of spreading out, focus on ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological cancer multiple myeloma, in the latest stage of the medicine's renaissance.

Join us at Axtria Ignite 2025 on 4th to 5th June to explore and lead in the agentic era. Learn from industry experts and leaders shaping the future of business.

Explore this exclusive interview with Remco op den Kelder as he answers 12 insightful questions that provide a unique glimpse into his life and perspectives.

AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, which the company has said could be a blockbuster new indication for the drug. The European Commission has cleared ...